EVs could serve as a novel source for genotyping BRAF or as biomarker of disease progression, since V600 mutation was detected in cancer cell line- and in body fluid-derived EVs in various cancers (Table 1), and corresponded to disease state, prognosis or survival (Hong et al., 2009; Thakur et al., 2014; Hao et al., 2017; Klump et al., 2018; García-Silva et al., 2019; Pasqualetti et al., 2019; Song et al., 2019). Here, BRAF is linked to cancer.